Rocket Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript
All right, good morning. Let's kick off our next session. It is my pleasure to introduce Gaurav Shah, CEO, and Meg Dodge, head of IR from Rocket Pharmaceuticals.
Welcome.
Very exciting to be hosting you again this year.
I have a lot of questions prepared, but before we get to that, I want to kick it off too. To Gaurav for opening remarks.
Rich, thanks for having us.
It's great to be back.
This is a very exciting year for Rocket Pharma. We are a gene therapy company.
We are focused, laser focused on cardiovascular genetic medicines, especially rare diseases where there's a high unmet need and where there are no alternative treatments other than heart transplant, which can be devastating in most cases.
So our focus has shifted over the years. We started off as an ex vivo lentiviral-based company with three programs in the clinic, one of which got approved. We're very
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
